Quantum Genomics Société Anonyme reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 0.0101 million compared to EUR 2.91 million a... Quantum Genomics Société Anonyme reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 0.0101 million compared to EUR 2.91 million a year ago. Net loss was EUR 1.99 million compared to EUR 8.85 million a year ago.
Quantum Genomics is a France-based biopharmaceutical company that develops and commercializes APA inhibitor drugs for the treatment of arterial hypertension and heart failure.